Filing Details

Accession Number:
0001209191-19-006625
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-02-01 20:09:01
Reporting Period:
2019-02-01
Accepted Time:
2019-02-01 20:09:01
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1337553 Aerie Pharmaceuticals Inc AERI Biological Products, (No Disgnostic Substances) (2836) 203109565
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1590001 C. Casey Kopczynski C/O Aerie Pharmaceuticals, Inc.
4301 Emperor Blvd., Suite 400
Durham NC 27703
Chief Scientific Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2019-02-01 9,500 $46.03 97,243 No 4 S Direct
Common Stock Disposition 2019-02-01 1,500 $47.02 95,743 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
Footnotes
  1. Following the sales reported on this Form 4, the reporting person's Rule 10b5-1 plan dated May 22, 2018 is completed.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions pursuant to the reporting person's Rule 10b5-1 plan at prices ranging from $46.00 to $46.15, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.